All PlansAdministrativeMedium impact
08.00.74ac, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Pharmacy
We identified it
Jul 2, 2026
Summary
Failed to analyze policy change